Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study - Passaro, A; Wang, J; Wang, Y; MARIPOSA-2 Investigators (Ann Oncol, 2024)